JPRN-UMIN000041453已完成未知
Adverse events of combined Dabrafenib Plus Trametinib in the treatment of tumors: a systematic review and meta-analysis. - Adverse events of combined Dabrafenib Plus Trametinib in the treatment of tumors: a systematic review and meta-analysis.
3-9 Fukuura, Kanazawa, Yokohama 236-0004, Japan0 个研究点开始时间: 2020年8月18日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Others,meta-analysis etc
入排标准
- 年龄范围
- 12years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Without frequency or category of adverse event
研究者
相似试验
尚未招募
Unknown
A phase II, open-label study of dabrafenib plus trametinib in patients with advanced solid tumor having BRAF V600E mutation or clinically actionable BRAF gene alterationsKCT0008405The Catholic University of Korea, Seoul St. Mary's Hospital30
撤回
2 期
Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid CancerThyroid Gland Anaplastic CarcinomaNCT04739566Saint Petersburg State University, Russia
进行中（未招募）
1 期
Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by SurgeryMetastatic Thyroid Gland CarcinomaUnresectable Thyroid Gland CarcinomaNCT01947023National Cancer Institute (NCI)23
进行中（未招募）
不适用
Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete ResectionMelanomaNCT04666272Novartis Pharmaceuticals78
招募中
2 期
Dabrafenib and Trametinib in pediatric patients with refractory advanced Solid Tumors with BRAF V600 mutations12 months to 15 year- old patients with unresectable or refractory solid cancer with BRAF V600JPRN-jRCTs011220017Kinoshita Ichiro28